KOELIS Inc.
$73.0K 234 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Omniscient Neurotechnology America Ltd
Omniscient Neurotechnology America Ltd reported $73,178.14 across General Payments, Research, and Ownership to 72 physicians and teaching hospitals across 72 transactions.
- $73.2K Below-median payer
- All-tracks total
- 72 Below-median volume
- Transactions
- 72 Below-median reach
- Recipients
- +$27.9K
- General Payments vs PY2023
Omniscient Neurotechnology America Ltd reported $73,178.14 across all CMS Open Payments tracks (General + Research + Ownership) to 72 physicians and teaching hospitals in Program Year 2024 - ranking #1262 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $73,178.14, averaging $1.0K per recipient.
Omniscient Neurotechnology America Ltd's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
17/100
Total payments
F
11/100
Transaction volume
F
10/100
Physician reach
F
11/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer omniscient-neurotechnology-america-ltd Omniscient Neurotechnology America Ltd
$73.2K · #1262/1,925 · 0.0% industry · PY2024
- TOT $73.2K
- RANK #1262
- SHARE 0.0%
- TXN 72
- RCP 72
- CAT 3
- GEN $73.2K
- ΔGEN +$27.9K
- TOP1 45.2%
- PY 2024
Volume peers
Nearest volume peer: KOELIS Inc. ($73.0K)
Omniscient Neurotechnology America Ltd sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Omniscient Neurotechnology America Ltd's CMS-reported General Payments increased by $27.9K (+61.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: OMNISCIENT NEUROTECHNOLOGY AMERICA LTDPY2023: OMNISCIENT NEUROTECHNOLOGY AMERICA LTDPY2024: Omniscient Neurotechnology America Ltd. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $45,253.54
- PY2024
- $73,178.14
What the Data Shows for Omniscient Neurotechnology America Ltd
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Omniscient Neurotechnology America Ltd that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
Of the 3 general-payment categories charted below, "Consulting Fee" is the largest at $60.1K across 25 transactions, 82.2% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Omniscient Neurotechnology America Ltd made 3 types of general payments. "Consulting Fee" is the largest category at $60.1K, 82.2% of General Payments.
How Omniscient Neurotechnology America Ltd divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $60.1K | 25 | 82.2% |
| Travel and Lodging | $8.3K | 9 | 11.4% |
| Food and Beverage | $4.7K | 38 | 6.4% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $71,169.14 (97.3%) of $73,178.14 in this company's General Payments records across 15 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Omniscient Neurotechnology America Ltd
The five named recipients with the highest reported General Payments from this company
- 1
RANDY Scott D'AMICO M.D.
$33,093.46 across 27 reported transactions
- 2
Michael Ivan M.d.
$22,580.35 across 11 reported transactions
- 3
Simon Hanft M.d.
$14,598.40 across 12 reported transactions
- 4
Jonathan Sherman
$515.05 across 4 reported transactions
- 5
Zachary Hickman
$381.88 across 3 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Omniscient Neurotechnology America Ltd ranks #1262 of 1,925 by total payments (bottom 34% by spend) but is notably more concentrated than that alone would suggest -- #518 of 1,838 by HHI (top 28% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Bristol Myers Squibb Company : $1.0M total payments, HHI 3447
- Collegium Pharmaceutical, Inc. : $1.5M total payments, HHI 3442
- Granata Bio Corporation : $5.5K total payments, HHI 3437
- American Rheumatology Network, LLC : $2.8M total payments, HHI 3431
- Biocircuit Technologies Inc : $69.8K total payments, HHI 3424
- Organ Recovery Systems, Inc. : $356.7K total payments, HHI 3422
- Omniscient Neurotechnology America Ltd (this company) : $73.2K total payments, HHI 3397
- FlexDex Inc. : $350.51 total payments, HHI 3376
- Seres Therapeutics, Inc. : $132.4K total payments, HHI 3375
- Orthopedic Sciences, Inc. : $4.0K total payments, HHI 3369
- L&k Biomed Co. , Ltd. : $864.8K total payments, HHI 3358
- Nidek Incorporated : $16.8K total payments, HHI 3356
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Omniscient Neurotechnology America Ltd's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Omniscient Neurotechnology America Ltd.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Omniscient Neurotechnology America Ltd.
Showing 6 of 1,924 companies with CMS-reported payment data.
Mevion_Medical_Systems_Inc
$73.7K 71 recipients
Compare payment profiles
Clariance SAS
$73.8K 57 recipients
Compare payment profiles
Community Blood Center
$72.5K 65 recipients
Compare payment profiles
Lightbody Medical Technologies Inc
$74.3K 678 recipients
Compare payment profiles
Merete Technologies, Inc
$72.1K 29 recipients
Compare payment profiles
Put this to use
Omniscient Neurotechnology America Ltd ranks #1262 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Omniscient Neurotechnology America Ltd. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.